Abstract
Hematopoietic stem cell transplants can be lifesaving for patients with hematologic malignancies. Donor sources for allogeneic transplants include bone marrow, peripheral blood stem cells, and cord blood. Cord blood has several advantages over adult stem cell sources, including no risk to the donor, more rapid time to transplant, and less stringent human leukocyte antigen (HLA) matching requirements. The major disadvantage of cord blood transplant is low cell dose, leading to delayed engraftment. Several experimental strategies have shown promise in overcoming this disadvantage and include methods to expand or improve homing of cord blood hematopoietic stem cells.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
